Acorda Therapeutics Inc
Most Recent
Who Is Eyeing Acorda Therapeutics?
On October 3, Acorda Therapeutics had a consensus 12-month target price of $22.89, which represents an ~18.11% return on investment over the next 12 months.
Mylan’s Recently Launched Generic Version of Ampyra
On September 21, Mylan (MYL) launched its authorized generic version of Acorda Therapeutics’ Ampyra, which is used for improvement in walking for adults who have multiple sclerosis.
Why Axovant Sciences Stock Is Soaring
Between March 31 and June 8, Axovant Sciences (AXON) stock rose ~284% from $1.69 to $4.80.
Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”
Exploring Acorda Therapeutics’ Financial Performance
In fiscal 2017, Acorda Therapeutics (ACOR) generated total revenue of $588.2 million, compared with $519.6 million in fiscal 2016.
Why Acorda Therapeutics is Focused on Inbrija
Acorda Therapeutics (ACOR) generated $543 million from Ampyra sales in fiscal 2017.
Analysts’ Ratings for FibroGen and Its Peers in April 2018
Of the seven analysts covering FibroGen in April, five have given the stock “strong buy” ratings, while two have given it “hold” ratings.
A Look at Alkermes’ Diabetes Product Portfolio
According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.